{"disease":{"id":"atypical-meningioma","name":"atypical meningioma"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT00919750","title":"Collecting and Storing Blood and Brain Tumor Tissue Samples From Children With Brain Tumors","phase":"","overall_status":"COMPLETED","enrollment_count":1258,"lead_sponsor_name":"Children's Oncology Group","has_results":false},{"nct_id":"NCT02973256","title":"Oncological Care for Patients With Meningioma","phase":"","overall_status":"UNKNOWN","enrollment_count":1204,"lead_sponsor_name":"University Hospital, Montpellier","has_results":false},{"nct_id":"NCT05793034","title":"Predictive Factors for Survival in Aggressive Meningiomas","phase":"NA","overall_status":"RECRUITING","enrollment_count":250,"lead_sponsor_name":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","has_results":false},{"nct_id":"NCT03173950","title":"Immune Checkpoint Inhibitor Nivolumab in People With Recurrent Select Rare CNS Cancers","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":133,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT04761653","title":"Study of the Inflammatory Microenvironment in Atypical Meningiomas","phase":"","overall_status":"UNKNOWN","enrollment_count":84,"lead_sponsor_name":"Central Hospital, Nancy, France","has_results":false},{"nct_id":"NCT04501705","title":"Apatinib in the Treatment of Recurrent Atypical/malignant Meningioma in Adults","phase":"NA","overall_status":"RECRUITING","enrollment_count":29,"lead_sponsor_name":"Beijing Sanbo Brain Hospital","has_results":false},{"nct_id":"NCT03016091","title":"A Trial of Pembrolizumab for Refractory Atypical and Anaplastic Meningioma","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":18,"lead_sponsor_name":"Rabin Medical Center","has_results":true}],"total":7},"guidelines":[],"source":"Drug Landscape verified database"}